NLRP3 and Parkinson disease: Both in vitro and in vivo models of Parkinson’s disease have suggested a link between the aggregation of α-synuclein, increased mitochondrial ROS, and cathepsin B release with the activation of microglial NLRP3 inflammation-mediated pyroptotic cell death of dopaminergic neurons in the substantia nigra[61–63].